Oxytocin antagonist (OTA), TT-235, was developed by our group and shown to inhibit either
spontaneous or oxytocin-induced uterine contractions in primates. The purpose of the …

One of the primary methods used to screen the development of oxytocin antagonists (OTAs)
is the rat oxytocic bioassay. The purpose of this study was to determine whether the rat …

Objective: To ascertain the relative activity of five oxytocin antagonists (OTAs) in vivo in a
tethered pregnant baboon model and compare these results to previously reported affinities …

Objective: A potent, long-acting oxytocin antagonist produced in our laboratory (ANTAG-III)
can inhibit uterine response to oxytocin in the rat and baboon for hours and even days. The …

Objectives To determine whether: 1. oxytocin receptor antagonists influence spontaneous
contractions of myometrium from humans, non-human primates and rodents (in vitro), and 2 …

Spontaneous and induced uterine contractions in the rat were found to be inhibited by a
novel and selective oxytocin receptor antagonist GSK221149A (3 R, 6 R)-3-Indan-2-yl-1-[(1 …

Contraction of the uterus is critical for parturient processes. Insufficient uterine tone, resulting
in atony, can potentiate postpartum hemorrhage; thus, it is a major risk factor and is the main …

Uterine contractions were induced with oxytocin in anesthetized pregnant baboons (Papio
anubis) at three stages of pregnancy (days 140, 156, and 169; normal gestation length, 184 …

We attempted to characterize the ability of a new oxytocin derivative, 1-deamino [D-Tyr
(Oethyl) 2, Thr 4, Orn 8] vasotocin (ORF 22164), to antagonize the action of oxytocin in …

L-366,509, a member of a novel class of nonpeptidyl compounds, has been characterized
as an orally active oxytocin (OT) antagonist. L-366,509 exhibits a moderate binding affinity …